Posted by Michael Wonder on 07 Feb 2024
Bristol Myers Squibb announces acceptance of US and EU regulatory filings for neo-adjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo in resectable non-small cell lung cancer
7 February 2024 - Applications based on results from CheckMate-77T, the company’s second positive Phase 3 randomised trial with an immunotherapy-based combination for the treatment of non-metastatic non-small cell lung cancer.
Bristol Myers Squibb today announced two regulatory acceptances for applications for neo-adjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo for the peri-operative treatment of resectable stage IIA to IIIB non-small cell lung cancer.
